Introduction
The G protein coupled receptor (GPCRs) super-family comprises of ~800 proteins which respond to a variety of ligands to create intracellular responses via G proteins, β -arrestins and other downstream M O L # 8 4 5 0 9
5 crystal structure used to aid discovery of a novel chemical series of receptor antagonists (Congreve et al., 2012; Langmead et al., 2012 ).
Many models have been developed to describe receptor activation (for example see De Lean et al., 1980; Samama et al., 1993 ) the simplest of which is the two-state model ( Fig. 1 ; Leff, 1995) that describes receptor existing in active (R*) or inactive (R) forms. The equilibrium between R and R* is defined by the isomerization constant 'L' (L=R*/R). Although the two-state model does not account for such phenomena as biased agonism or multiple conformations that exist between R and R* (see Perez et al., 1996) it is extremely useful conceptually, describing interactions of many GPCR ligands.
Agonists are described to bind with higher affinity to R*, inverse agonist to R whilst neutral antagonists bind with equal affinity to R and R*.
At the inactive-state A 2A StaR there is a significant decrease in the affinity of agonists (CGS21680 and NECA) at the receptor with a corresponding slight increase in inverse agonist affinity . Agonist affinity at a receptor fully locked into the R* conformation is expected to be increased compared to wild-type receptor (as demonstrated at a constitutively active mutant of the β 2 adrenoreceptor; Samama et al., 1993) . At the active-state adenosine A 2A receptor constructs, the affinity of agonists such as NECA, CGS21680 and ATL146e are unaltered compared to the wild-type although there is significant decrease in inverse agonist affinity (Lebon et al., 2011b) suggesting the receptor is stabilised in a conformation towards the fully active state.
M O L # 8 4 5 0 9
6 Here we show that measuring changes in ligand binding affinity at isolated active and inactive A 2A receptor states can be used to predict and interpret findings from functional assays in a systemindependent manner. Furthermore, we demonstrate that ligand docking into active and inactive-state crystal structures supports the pharmacology and demonstrates the importance of receptor conformation in crystal structure determination and drug design.
8 serum, 1 % penicillin/streptomycin mixture and 10 µg/mL blasticidin S hydrochloride at 37 °C in a humidified air; 5% CO 2 atmosphere.
Generation of a stable adenosine A 2A(1-316) receptor cell line
T-REx CHO cells were transfected with pcDNA5/TO containing A 2A(1-316) using Genejuice (as per manufacturer's instructions). After 48 h media was replaced with medium supplemented 200 µg/mL hygromycin B to select for stably expressing clones. Single colonies were selected and grown in media supplemented with doxycycline (1 µg/mL; 16 h) before being screened for receptor expression using a cAMP accumulation assay.
Radioligand binding assays
Cells were harvested and membranes prepared as previously described .
Radioligand binding assays were carried out using membranes prepared from CHO cells transiently (Zhukov et al., 2011) were used to define the cavity of the grid; however, no constraints were added in the grid generation to ensure that subsequent dockings were not biased in any way. Glide XP docking was carried out on all of the ligands in question with 10 poses per ligand being stored. The poses were then assessed against the BPM data and the best solution identified.
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1; P=0.86, P=0.44, P=0.07, P=0.38, respectively; unpaired two-tailed t-test) . Interestingly, theophylline and caffeine showed slightly decreased affinities at StaR2 (1-316) (P<0.05 for theophylline, and P<0.05 for caffeine; unpaired two-tailed t-test), whilst the affinity of istradefylline remained unaltered at both agonist and inverse agonist (StaR2 (1-316) ) constructs (P=0.39).
The affinity data from Table 1 respond better to agonist and inverse agonists as there was a larger response signal (Bennett, 2011) and as agonist and inverse agonist affinities were not significantly different at A 2A(1-316) compared to A 2A (Table 1; Supplementary Table 2 ) the T-Rex-CHO-A 2A(1-316) cell line was used for all functional studies.
Initial studies were carried out to establish ligand pharmacology under different levels of receptor induction (and hence expression and constitutive activity). Over a range of doxycycline concentrations (0 -10 ng/ml), basal cAMP levels could be titrated such that a range of responses could be observed. Receptor expression levels at each of the doxycycline concentrations were
14 activity and a full NECA response could be seen, however there was no window for inverse agonism to be detected (Fig. 3a) . In contrast, when fully induced with a high concentration of doxycycline (10 ng/mL), it was possible to elevate the basal level of cAMP to such a level that no further NECA response could be observed, although inverse agonism could be detected (Fig. 3b) . Using a doxycycline concentration of 0.3 ng/ml it was possible to achieve an intermediate level of constitutive activity to enable the detection of both positive and inverse agonism ( Fig. 3C ; Supplementary Table   4 ). Thus, only using a very specifically designed functional assay is it possible to functionally delineate the pharmacology of inverse agonists and either partial inverse agonists or neutral antagonists.
Cells were challenged with NECA causing a concentration-dependent increase in cAMP accumulation levels ( Fig. 4A ). Incubating cells with preladenant decreased cAMP levels in a concentrationdependent manner to the level seen in the absence of doxycycline-induced receptor expression except at high doxycycline concentrations where preladenant appeared to act as a partial inverse agonist (Fig.   4B ). Theophylline appeared to have no effect on cAMP accumulation levels at all doxycycline concentrations tested indicating neutral antagonism (Fig. 4C ). Istradefylline and caffeine, which also showed little preference in binding to active and inactive state receptor constructs ( Fig. 2 ; Table 1 Supplementary Fig. 3 ).
In contrast, the neutral antagonist caffeine, a small fragment-sized molecule, appears to dock equally well into the binding site of the active state A 2A receptor structure (in a position similar to the xanthine portion of XAC), suggesting that binding of caffeine does not sterically preclude the adenosine A 2A
receptor from adopting an active state when bound (Fig. 5D ).
It is worth noting that in all active state StaRs the stabilizing mutations are outside the ligand binding domain, meaning that no mutations are within 5 Å of the binding site of the ligands tested in this This article has not been copyedited and formatted. The final version may differ from this version. Based on previous site-directed mutagenesis (SDM) data (Zhukov et al., 2011) and guided by binding and functional data, the clinically evaluated adenosine A 2A receptor 'antagonists', preladenant and istradefylline were docked into the binding site of the structure determined in complex with ZM241385 (3PWH; Fig. 6A , 5B). Preladenant is shown bound in a similar conformation to ZM241385; the triazolotriazine core and attached furan ring system both hydrogen bond to N253 6.55 .
The aryl piperidine substituent of preladenant, whilst chemically distinct from the phenolic substituent of ZM241385, occupies the similar cleft between TM domains 1 and 7 (Fig. 6A ). Due to its bulk, preladenant is expected to extend some way outside of the agonist binding pocket as defined by the NECA-bound crystal structure (2YDV); furthermore the furan ring sits in a similar position to that of ZM241385, sterically preventing the inward movement of H250 6.52 ; this pose clearly explains why it shows robust inverse agonist activity. For the placement of istradefylline in the binding site, previous SDM experiments show that istradefylline binding is less affected by alanine mutation of either I66
2.64 or Y271 7.36 compared to the effect on both XAC and ZM241385 (Zhukov et al., 2011) . Thus the SDM-guided docking of istradefylline shows, similarly to caffeine, its carbonyl oxygen from C6
forming a hydrogen bond to N253 6.55 and the vector of the ligand placement pointing directly up towards the extracellular surface, but crucially still contained within the binding site surface defined by the NECA-bound agonist structure (2YDV; Fig. 6C ), rationalizing the neutral antagonist profile observed.
Conversely, we sought to understand the potential interaction of NECA with the inactive conformation based on known structure (3PWH; Fig 6C) . Whilst NECA can fully fit into the inactive state binding site, the significant movements of TM3 and TM7 (described in Dore et al., 2011) receptors progressively stabilized into both inactive and active states to predict their molecular efficacy. Affinity ratios were then qualitatively compared with data generated using a functional cAMP assay at different levels of constitutive activity.
Ligands can display a wide spectrum of efficacies; they can act as full or partial agonists, appear silent (neutral antagonist) or display partial to full inverse agonism. The two-state model of receptor activation (Leff, 1995) ascribes ligand efficacy as a ratio of its affinity for the inactive (R) and active (R*) receptor states; agonists have higher affinity for R*, inverse agonists have higher affinity for R whilst neutral antagonists do not select between conformations. Although the two-state model is likely to be over-simplistic in describing GPCR pharmacology (i.e. it does not account for multiple conformations that exist between inactive/fully active receptor and differences in activation states that result in biased agonism), it is extremely useful conceptually, describing the interactions of many GPCR ligands (Canals et al., 2012) .
The data generated herein appears to be accommodated approximately within the two-state mechanism. The prototypical adenosine receptor agonist, NECA, displays significantly lower affinity at the inactive state A 2A receptor, the 'antagonists' ZM241385, preladenant, SCH58261 and XAC bind with higher affinity to the inactive state i.e. act as inverse agonists. Istradefylline, caffeine and theophylline bind with similar affinities to both inactive and active states and would be defined as neutral antagonists.
We have previously demonstrated that adenosine A 2A receptor number and constitutive activity can be titrated using an inducible expression system (Lebon et al., 2011b) . By optimising the levels of induction, a system was created allowing measurement of agonist and inverse agonist responses ( 3). We confirmed that affinity ratios correlated with efficacy in vitro; ZM241385, preladenant, SCH58261 and XAC acted as inverse agonists and NECA acted as an agonist in the cAMP assay.
Based on binding studies, istradefylline, caffeine and theophylline were predicted to act as neutral antagonists; this was verified in the functional assays where all three compounds displayed essentially neutral antagonism, though caffeine did display very weak partial inverse agonist efficacy (Fig 4,   Supplementary Fig 1) .
Measuring affinity constants for isolated GPCR conformations is not trivial; functional effects depend not only on efficacy but on other factors such as receptor expression and signal amplification between receptor and endpoint measured. At low levels of receptor expression NECA acts as an agonist of the adenosine A 2A receptor; however when receptor density is increased, there is a point where constitutive activity becomes so great that NECA can no longer elicit a response above basal (due to the maximal system response being reached; Fig. 3B ). For the inverse agonists preladenant, ZM241385, SCH58261 and XAC, responses could only be measured in a system where there was sufficient basal activity to allow a 'window' for reversal; whilst if receptor density is further increased it reaches a point where these ligands appear to act as partial inverse agonists ( Fig. 4 ; Supplementary   Fig. 1 ).
Using the crystal structures of both the active state and inactive state (Lebon et al., 2011b; Dore et al., 2011) adenosine A 2A receptor we sought to rationalise the differences in pharmacology of the ligands tested in this study. The change in shape and size of the binding pocket upon agonist binding is marked (Dore et al., 2011; Lebon et al., 2011b) istradefylline extends perpendicular to the membrane but is equally able to be accommodated in active and inactive state binding pocket. Thus, both affinity data and the docking mode predict for istradefylline to display neutral antagonism, a profile confirmed in functional analysis.
A similar approach was taken for predicting the binding mode of preladenant. Due to their chemical similarity, preladenant is predicted to bind in a similar mode to that of ZM241385 with the triazolotriazine core and furan ring forming H-bonding interactions with N253 6.55 . As for ZM241385, the position of the furan ring is predicted to sterically prevent inward movement of H250 6.52 that it seen upon receptor activation. In addition, due to its increased bulk, the aryl-piperidine moiety of preladenant is expected to extend even further than ZM241385 or XAC beyond the extracellularfacing surface of the agonist binding site (Fig. 6A-B) ; these observations explain why preladenant has such low affinity for the active state receptor and hence displays such robust inverse agonist behavior. Here we demonstrated that by determining ligand affinities at the adenosine A 2A receptor isolated at both active and inactive states it is possible to make qualitative, system-independent assessment of ligand pharmacology. This could help distinguish neutral antagonists from inverse agonists, which is hard to do functionally in vitro where there is a low level of constitutive activity in the system
, as inverse agonists will be indistinguishable from neutral antagonists. This is highly relevant; inverse agonists may be therapeutically useful in the treatment of diseases linked with constitutive receptor activation such as severe Jansen-type metaphyseal chondrodysplasia (Schipani et al., 1995) , fragile X-linked disorder (Ronesi et al., 2012) or autoimmune diseases (de Ligt et al., 2000) . Furthermore, we demonstrated that analysis of putative docking modes into the active and inactive state crystal structures supports the functional observations and permits an in silico assessment of ligand pharmacology. The concept of predicting whether a compound has a propensity This article has not been copyedited and formatted. The final version may differ from this version. 22 to behave as an agonist, neutral antagonist or inverse agonist in a cellular or in vivo setting is a potentially powerful tool for researchers (Fig. 7) . This article has not been copyedited and formatted. The final version may differ from this version. form. Inactive receptor may isomerize to the active form (R*) even in the absence of agonist -a property known as constitutive activity. Once ligand is bound, the receptor can exist in two states, occupied (AR) or occupied and activated (AR*), the latter being the species that couples to G protein (Strange, 2000) . The position of equilibrium between R and R* will depend on the isomerisation constant (L) i.e. on the conformational change that takes place. An inverse agonist will bind stronger to R keeping the receptor in the inactive state (form AR) whilst an agonist will bind stronger to R* pushing the equilibrium towards AR*. K A and K A /α are the equilibrium constants for agonist binding to the receptor conformations R and R*, respectively; α defines the efficacy of A. (purple stick) co-crystal structure (3PWH) and c. XAC (salmon stick) co-crystal structure (3REY) overlaid the NECA co-crystal structure 2YDV. In the inactive state crystal structures TM 1 is significantly moved outwards compared to the NECA-bound structure. ZM241385 and XAC do not fully fit into the binding pocket defined in the agonist crystal structure. d. The co-crystal structure of caffeine (pink stick) (3RFM) reveals that due to its smaller size caffeine can be accommodated in the agonist binding pocket. approaches to GPCR pharmacology using StaR technology. By using isolated receptor conformations, it is possible to b. screen ligands by in vitro binding to identify compounds which bind preferentially to a given conformation or c. solve the structure of a defined conformation and de novo design or screen in silico for ligands which bind to that conformation. In each case, the selectivity for the given conformation defines the pharmacology.
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